Trump New Executive Orders Could Impact Indian Pharma Exports
News: President Donald Trump’s recent executive orders prioritize domestic pharmaceutical manufacturing in the U.S., posing major challenges for Indian drug exporters, especially in the generics market, according to a Nuvama Research report.
The move aims to re-shore production of APIs, KSMs, and raw materials, potentially disrupting global drug supply chains and reducing India’s cost advantage.
The orders also propose faster U.S. regulatory clearances, stricter compliance for foreign facilities, and higher fees for overseas manufacturers.
A possible requirement to disclose API origins could expose India’s reliance on Chinese imports, adding to scrutiny.
These measures reflect a broader focus on U.S. biosecurity and may significantly restructure the U.S. generics supply chain if fully implemented.
Source: The Economic Times
Join The Community
Recent News
-
Container Shipping Rates Climb Following U.S.-China Tariff Truce, Though Growth Shows Signs of Slowing -
India Vital to Global Supply Chains and Deserves G7 Inclusion: Canadian Prime Minister -
India Developing Alternative Supply Chains Amid China’s Rare Earth Export Restrictions: Piyush Goyal -
Goyal Explores Indian Shipping Opportunities in Talks with Singapore’s Gan Kim Yong -
India Aims to Triple Air Cargo Handling Capacity by 2030, Says PM Modi
2 Comments